olomorasib

AXP000032.1 · Targeted small molecule

Platform
small molecule
Targets
KRAS
Originator
Eli Lilly and Company
Sponsor
Eli Lilly and Company

Names

NameTypeSource
olomorasibpreferred name, INNcurator, ncit
LY3537982codencit

Cross-references

NCI Thesaurus
C181751
Wikidata
Q133445577
FDA UNII
C2VJ83PSN7

Approvals

No regulatory approval recorded.

Clinical trials (18)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07890714A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/22026-10-162029-09-30268Non-small Cell Lung Cancer; Urothelial Cancer
NCT07814417A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruitingPhase 22026-102028-1150Colorectal Neoplasms
NCT07639242Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLCSuspendedPhase 22026-102030-06-2160Locally Advanced NSCLC; Lung Cancer; Lung Cancer (NSCLC); Metastatic NSCLC - Non-Small Cell Lung Cancer
NCT07794592A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy ParticipantsRecruitingPhase 12026-08-282026-1024Healthy Volunteers
NCT07227025A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung CancerRecruitingPhase 1/22026-03-032028-11-3060Carcinoma, Non-Small-Cell Lung
NCT07439250A Study of Olomorasib (LY3537982) in Healthy ParticipantsCompletedPhase 12026-03-022026-04-1715Healthy
NCT07124013A Study of Olomorasib (LY3537982) in Healthy Japanese ParticipantsCompletedPhase 12025-09-162026-01-05191Healthy
NCT07137689A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney FunctionCompletedPhase 12025-08-182026-04-1032Renal Insufficiency
NCT07044271A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsCompletedPhase 12025-07-112025-11-08120Healthy
NCT06890598Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingPhase 32025-03-272029-05700Carcinoma, Non-Small-Cell Lung
NCT06719128A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy ParticipantsCompletedPhase 12024-12-062025-08-2546Healthy; Hepatic Insufficiency
NCT06235983A Study of LY3537982 in Chinese Participants With Advanced Solid TumorsCompletedPhase 12024-02-292025-07-0212Advanced Solid Tumors
NCT06119581A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingPhase 32023-12-212027-111264Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
NCT06111521A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy ParticipantsCompletedPhase 12023-10-272024-04-0135Healthy
NCT05901311A Study of [14C]-LY3537982 in Healthy ParticipantsCompletedPhase 12023-06-052023-08-1016Healthy
NCT05860933A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy ParticipantsCompletedPhase 12023-05-082023-08-2830Healthy
NCT05824858A Study of the Effect of Food on LY3537982 in Healthy ParticipantsCompletedPhase 12023-04-122023-06-1748Healthy
NCT04956640Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active not recruitingPhase 1/22021-07-192027-04540Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms

Recent changes

SeenTrialChangeDetailTitle
2026-11-12NCT07890714new trialA Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41319864Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026name in title: olomorasib
PMID 41820335Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.Nature communications2026name in title: olomorasib
PMID 41940628SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.Future oncology (London, England)2026cited by trial NCT06119581
PMID 42823821SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.Future oncology (London, England)2026cited by trial NCT06890598

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41663526Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases.Cancer gene therapy2026name in abstract: olomorasib
PMID 41784211A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.Cancer investigation2026name in abstract: olomorasib
PMID 42082482Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models.Nature communications2026name in title: olomorasib
PMID 42511798KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.International journal of molecular sciences2026name in abstract: olomorasib
PMID 42551924[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].Gan to kagaku ryoho. Cancer & chemotherapy2026name in abstract: olomorasib
PMID 42622884KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Medical oncology (Northwood, London, England)2026name in abstract: olomorasib
PMID 40274247KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials.Critical reviews in oncology/hematology2025name in abstract: olomorasib
PMID 40597785The complex journey of targeting RAS in oncology.BMC cancer2025name in abstract: LY3537982
PMID 40640254Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations.Scientific reports2025name in title: LY3537982

Notes

KRAS G12C covalent (second generation).

How to cite

olomorasib (AXP000032.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000032.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.